---
title: "3 High-Risk/High-Reward Stocks With 100%+ Upside Potential, According to Analysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299668753.md"
description: "Analysts identify three high-risk, high-reward stocks with over 100% upside potential: Zura Bio (ZURA), Aclaris Therapeutics (ACRS), and Adtran Holdings (ADTN). All hold Strong Buy ratings. Zura Bio, a clinical-stage biotech developing immune-boosting treatments, leads with approximately 414% upside based on an average price target of $22.67, driven by bullish sentiment regarding its pipeline despite lacking commercial revenue."
datetime: "2026-09-21T16:59:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299668753.md)
  - [en](https://longbridge.com/en/news/299668753.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299668753.md)
generator: "portal-rs"
---

# 3 High-Risk/High-Reward Stocks With 100%+ Upside Potential, According to Analysts

Several high-risk, high-reward stocks come from companies that operate in industries where conditions change quickly. As a result, they carry great risk but also offer the potential for exceptional returns. Their success depends heavily on how well management delivers on its strategy and growth plans. On Wall Street, analysts continue to back some of them. Three such high-risk, high-reward stocks are Zura Bio (ZURA), Aclaris Therapeutics (ACRS), and Adtran Holdings (ADTN). They are all currently rated a Strong Buy and offer at least 100% upside. ZURA leads with more than 400% upside.

## **Zura Bio** (ZURA)

This is a clinical-stage biotech company based in San Diego, California. The firm is developing new treatments to boost the body's immune system and target inflammatory diseases.

Zura's lead asset is tibulizumab, internally known as ZB-106. This is an injection treatment being designed to block two key "alarm buttons" that cause the immune system to overreact and attack the body.

While Zura currently has no commercial revenue, bullish analysts are supportive of its expanding pipeline and funding base.

On Wall Street, ZURA has a Strong Buy consensus based on four Buy ratings issued over the past three months. This is based on the average price target of $22.67, which implies roughly 414% upside.

### Related Stocks

- [ZURA.US](https://longbridge.com/en/quote/ZURA.US.md)
- [ADTN.US](https://longbridge.com/en/quote/ADTN.US.md)
- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)

## Related News & Research

- [Goldman Sachs Increases Total Voting Rights in ADTRAN to 5.64% From 4.89%](https://longbridge.com/en/news/302314364.md)
- [Morgan Stanley cuts total voting rights in ADTRAN to 6.85% from 7.06%](https://longbridge.com/en/news/301999570.md)
- [Morgan Stanley lifts Adtran voting rights stake to 7.06% from 5.74%](https://longbridge.com/en/news/301502457.md)
- [Aclaris Therapeutics enters amended at-the-market equity sales agreement with Leerink, Cantor](https://longbridge.com/en/news/295151888.md)
- [Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZURA Stock News](https://longbridge.com/en/news/296659303.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**